NCT00850603View on ClinicalTrials.gov

Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®

PHASE4CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

May 31, 2003

Study Completion Date

November 30, 2004

Conditions
Meningococcal InfectionsMeningitis
Interventions
BIOLOGICAL

Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined

0.5 mL, Subcutaneous

BIOLOGICAL

Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined

0.1 mL, Subcutaneous

BIOLOGICAL

Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined

0.05 mL, Intradermal

BIOLOGICAL

Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined

0.1 mL, Intradermal

BIOLOGICAL

Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined

0.15 mL, Intradermal

Trial Locations (1)

18301

East Stroudsburg

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00850603 - Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune® | Biotech Hunter | Biotech Hunter